by DealForma Analysts | Jun 13, 2019 | Analysis, M&A
Analysis | M&A Reverse mergers have been a relatively quick method for companies to gain a public listing as an alternative to IPOs. A private company looking to go public merges with a company that is already publicly traded and changes the ticker symbol....
by DealForma Analysts | Jan 22, 2019 | Analysis, Funding
Analysis | Funding Celgene’s recent acquisition offer by Bristol-Myers Squibb has raised attention to its prolific dealmaking history. We covered this in a recent article in Endpoints News. Celgene was also very active in venture round participation....
by DealForma Analysts | Sep 4, 2018 | Analysis, Partnership Deals
Analysis | Deals Data from the DealForma database and an analysis were prepared for a story published in Endpoints News looking at top dealmakers in recent biopharma partnerships. We applied certain criteria to filter for deals involving major R&D and commercial...
